Journal
ACS APPLIED MATERIALS & INTERFACES
Volume 10, Issue 34, Pages 28458-28470Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acsami.8b10426
Keywords
MDR; p-glycoprotein; curcumin; doxorubicin; In vivo tumor suppression
Funding
- Advanced Biomass R&D Center (ABC) of the Global Frontier Project - Ministry of Science and ICT [NRF-2015M3A6A2074238]
- Ministry of Science and ICT [NRF-2014M3A9E4064580, NRF-2016R1A2B4009619]
Ask authors/readers for more resources
Curcumin (CRC) has been widely used as a therapeutic agent for various drug delivery applications. In this work, we focused on the applicability of CRC as a nanodrug delivery agent for doxorubicin hydrochloride (DOX) (commercially known as Adriamycin) coated with poly (ethylene glycol) (PEG) as an effective therapeutic strategy against multidrug-resistant cancer cells. The developed PEG coated CRC/DOX nanoparticles (NPs) (PEG-CRC/DOX NPs) were well localized within the resistant cancer cells inducing apoptosis confirmed by flow cytometry and DNA fragmentation assays. The PEG-CRC/DOX NPs suppressed the major efflux proteins in DOX-resistant cancer cells. The in vivo biodistribution studies on HCT-8/DOX-resistant tumor xenograft showed improved bioavailability of the PEG-CRC/DOX NPs, and thereby suppressed tumor growth significantly compared to the other samples. This study clearly shows that curcumin nanoparticles could deliver DOX efficiently into the multidrug-resistant cancer cells to have potential therapeutic benefits.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available